Experimental Hematology
Volume 38, Issue 1 , Pages 38-45 , January 2010

Coexpression of CD44 variant isoforms and receptor for hyaluronic acid−mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status−independent predictor of poor outcome in diffuse large B-cell lymphomas

  • Sabine Nagel

      Affiliations

    • Institute of Pathology, Basel, Switzerland
    • Technical University of Berlin, Berlin, Germany
    • ,
  • Petra Hirschmann

      Affiliations

    • Institute of Pathology, Basel, Switzerland
    • ,
  • Stephan Dirnhofer

      Affiliations

    • Institute of Pathology, Basel, Switzerland
    • ,
  • Ursula Günthert

      Affiliations

    • Institute of Pathology, Basel, Switzerland
    • ,
  • Alexandar Tzankov

      Affiliations

    • Institute of Pathology, Basel, Switzerland
    • Corresponding Author InformationOffprint requests to: Alexandar Tzankov, M.D., Institute of Pathology, Schönbeinstrasse 40, CH 4031 Basel, Switzerland

Received 24 August 2009 ,Revised 19 October 2009 ,Accepted 20 October 2009.

References 

  1. Stein H, Warnke R, Chan W. Diffuse large B-cell lymphoma, not otherwise specified. In:  Swerdlow SH,  Campo E,  Harris NL, et al. editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: WHO Press; 2008;p. 233–237
  2. de Leval L, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology. 2003;43:509–528
  3. Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol. 2005;23:6351–6357
  4. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol. 2006;208:714–723
  5. Pileri SA, Dirnhofer S, Went P, et al. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology. 2002;41:482–509
  6. Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma. 2003;44(Suppl 3):41–47
  7. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  8. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282
  9. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–1947
  10. Shipp MA, Harrison DP, Anderson JR, et al. A predictive model for aggressive NHL: The international non-Hodgkin's Lymphoma Prognostic Factor Project. N Engl J Med. 1993;329:987–994
  11. Drillenburg P, Wielenga VJ, Kramer MH, et al. CD44 expression predicts disease outcome in localized large B cell lymphoma. Leukemia. 1999;13:1448–1455
  12. Horst E, Meijer CJ, Radaskiewicz T, et al. Expression of a human homing receptor (CD44) in lymphoid malignancies and related stages of lymphoid development. Leukemia. 1990;4:383–389
  13. Horst E, Meijer CJ, Radaszkiewicz T, Ossekoppele GJ, Van Krieken JH, Pals ST. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia. 1990;4:595–599
  14. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33–45
  15. Stauder R, Günthert U. CD44 isoforms—impact on lymphocyte activation and differentiation. Immunologist. 1995;3:78–83
  16. Günthert U, Johansson B. CD44-a protein family involved in autoimmune diseases and apoptosis. Immunologist. 2001;8:106–109
  17. Inagaki H, Banno S, Wakita A, Ueda R, Eimoto T. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma. Mod Pathol. 1999;12:546–552
  18. Ristamaki R, Joensuu H, Soderstrom KO, Jalkanen S. CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis. J Pathol. 1995;176:259–267
  19. Salles G, Zain M, Jiang WM, Boussiotis VA, Shipp MA. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood. 1993;82:3539–3547
  20. Stauder R, Eisterer W, Thaler J, Günthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood. 1995;85:2885–2899
  21. Terpe HJ, Koopmann R, Imhof BA, Günthert U. Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas. J Pathol. 1994;174:89–100
  22. Tzankov A, Pehrs AC, Zimpfer A, et al. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol. 2003;56:747–752
  23. Mielgo A, van Driel M, Bloem A, Landmann L, Günthert U. A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ. 2006;13:465–477
  24. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055–1061
  25. Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem. 2001;276:46024–46030
  26. Hamilton SR, Fard SF, Paiwand FF, et al. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem. 2007;282:16667–16680
  27. Maxwell CA, McCarthy J, Turley E. Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions?. J Cell Sci. 2008;121:925–932
  28. Giannopoulos K, Mertens D, Buhler A, et al. The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia. 2009;23:519–527
  29. Zlobec I, Terracciano L, Tornillo L, et al. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. Gut. 2008;57:1413–1419
  30. Tzankov A, Went P, Zimpfer A, Dirnhofer S. Tissue microarray technology: principles, pitfalls and perspectives–lessons learned from hematological malignancies. Exp Gerontol. 2005;40:737–744
  31. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem. 2004;52:893–901
  32. Zlobec I, Terracciano L, Jass JR, Lugli A. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch. 2007;451:763–769
  33. Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma. In press.
  34. Tzankov A, Went P, Dirnhofer S. Prognostic significance of in situ phenotypic marker expression in diffuse large B-cell lymphomas. Biomarker Insights. 2007;2:403–417
  35. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008;93:193–200
  36. Tzankov A, Gschwendtner A, Augustin F, et al. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome. Clin Cancer Res. 2006;12:2125–2132
  37. Obermann EC, Csato M, Dirnhofer S, Tzankov A. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment. J Clin Pathol. 2009;62:754–756
  38. Kremmidiotis G, Ridings J, Hicks M, et al. Heterogeneity of CD44 expression among human B-cell subpopulations. Tissue Antigens. 1998;51:232–241
  39. Mythreye K, Blobe GC. Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cell Signal. 2009;21:1548–1558
  40. Eser B, Sari I, Canoz O, et al. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma. Am J Hematol. 2006;81:307–314
  41. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005;106:1164–1174
  42. Trowbridge IS, Lesley J, Schulte R, Hyman R, Trotter J. Biochemical characterization and cellular distribution of a polymorphic, murine cell-surface glycoprotein expressed on lymphoid tissues. Immunogenetics. 1982;15:299–312
  43. Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Günthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol. 1994;124:71–82

PII: S0301-472X(09)00401-9

doi: 10.1016/j.exphem.2009.10.010

Experimental Hematology
Volume 38, Issue 1 , Pages 38-45 , January 2010

Article Tools

* Image Usage & Resolution